• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Non-alcoholic fatty liver disease and psoriasis: So far, so near.非酒精性脂肪性肝病与银屑病:咫尺天涯。
World J Hepatol. 2015 Mar 27;7(3):315-26. doi: 10.4254/wjh.v7.i3.315.
2
Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?非酒精性脂肪性肝病与银屑病——是否存在共同的促炎网络?
J Dtsch Dermatol Ges. 2021 Apr;19(4):517-528. doi: 10.1111/ddg.14425. Epub 2021 Mar 25.
3
The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.依那西普对非酒精性脂肪性肝病、代谢综合征和银屑病患者肝纤维化风险的影响。
J Gastroenterol. 2013 Jul;48(7):839-46. doi: 10.1007/s00535-012-0678-9. Epub 2012 Oct 13.
4
Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.银屑病、非酒精性脂肪性肝病和心血管疾病:独特背景下的三种不同疾病。
World J Cardiol. 2016 Feb 26;8(2):120-31. doi: 10.4330/wjc.v8.i2.120.
5
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.代谢综合征、非酒精性脂肪性肝病与银屑病关节炎及银屑病患者的肝硬度。
Clin Rheumatol. 2019 Oct;38(10):2843-2850. doi: 10.1007/s10067-019-04646-7. Epub 2019 Jun 28.
6
Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach.肠病、肺病或皮肤病患者的非酒精性脂肪性肝病:需要多学科方法的炎症串扰。
World J Gastroenterol. 2021 Nov 7;27(41):7113-7124. doi: 10.3748/wjg.v27.i41.7113.
7
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.银屑病患者的非酒精性脂肪性肝病(NAFLD):系统性治疗对肝脏影响的综述
Psoriasis (Auckl). 2021 Dec 7;11:151-168. doi: 10.2147/PTT.S342911. eCollection 2021.
8
The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India.印度南部一项研究显示,银屑病患者中非酒精性脂肪性肝病的患病率增加。
Australas J Dermatol. 2012 Aug;53(3):190-7. doi: 10.1111/j.1440-0960.2012.00905.x. Epub 2012 Jun 6.
9
Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis.银屑病患者非酒精性脂肪性肝病的风险:一项系统评价和荟萃分析。
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):656-62. doi: 10.1111/jdv.12847. Epub 2014 Nov 21.
10
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.

引用本文的文献

1
Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris.寻常型银屑病患者中非酒精性脂肪性肝炎的发病率
Wien Med Wochenschr. 2025 Aug 29. doi: 10.1007/s10354-025-01107-6.
2
Biologic therapy for psoriasis is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD). A study on the association of cardiometabolic conditions with psoriasis treatment.银屑病的生物治疗与代谢功能障碍相关脂肪性肝病(MASLD)的发生有关。一项关于心脏代谢疾病与银屑病治疗相关性的研究。
Arch Dermatol Res. 2025 Jan 7;317(1):195. doi: 10.1007/s00403-024-03688-5.
3
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study.古塞库单抗治疗日本银屑病患者的安全性和有效性:上市后监测研究的 20 周中期分析。
J Dermatol. 2024 Jun;51(6):779-790. doi: 10.1111/1346-8138.17255. Epub 2024 May 15.
4
Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: A systematic review, meta-analysis, and trial sequential analysis.成年银屑病患者中非酒精性脂肪性肝病的患病率及风险:一项系统评价、荟萃分析和试验序贯分析
Medicine (Baltimore). 2024 May 3;103(18):e38007. doi: 10.1097/MD.0000000000038007.
5
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.代谢相关脂肪性肝病中双向免疫交叉对话。
Cell Metab. 2023 Nov 7;35(11):1852-1871. doi: 10.1016/j.cmet.2023.10.009.
6
Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease.低热量饮食对非酒精性脂肪性肝病银屑病患者的银屑病严重程度指数、甘油三酯、肝酶及生活质量的影响。
Reumatologia. 2023;61(2):116-122. doi: 10.5114/reum/162995. Epub 2023 May 10.
7
Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management.银屑病与代谢综合征共病:临床意义及最佳管理
Psoriasis (Auckl). 2022 May 25;12:113-126. doi: 10.2147/PTT.S293107. eCollection 2022.
8
Utility and Limitations of Transient Elastography to Monitor Hepatic Steatosis, Hepatic Fibrosis, and Methotrexate-Associated Hepatic Disease in Psoriasis: A Systematic Review.瞬时弹性成像在监测银屑病患者肝脂肪变性、肝纤维化及甲氨蝶呤相关肝病中的应用与局限性:一项系统评价
J Clin Aesthet Dermatol. 2021 Dec;14(12):24-28.
9
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.银屑病患者的非酒精性脂肪性肝病(NAFLD):系统性治疗对肝脏影响的综述
Psoriasis (Auckl). 2021 Dec 7;11:151-168. doi: 10.2147/PTT.S342911. eCollection 2021.
10
Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach.肠病、肺病或皮肤病患者的非酒精性脂肪性肝病:需要多学科方法的炎症串扰。
World J Gastroenterol. 2021 Nov 7;27(41):7113-7124. doi: 10.3748/wjg.v27.i41.7113.

本文引用的文献

1
Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis.接受肿瘤坏死因子-α抑制剂治疗的银屑病患者的血清脂肪细胞因子水平:一项回顾性分析结果
Int J Dermatol. 2015 Jul;54(7):839-45. doi: 10.1111/ijd.12706. Epub 2015 Apr 15.
2
Molecular pathways in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的分子途径
Clin Exp Gastroenterol. 2014 Jul 5;7:221-39. doi: 10.2147/CEG.S62831. eCollection 2014.
3
Obesity and the liver: nonalcoholic fatty liver disease.肥胖与肝脏:非酒精性脂肪性肝病
Transl Res. 2014 Oct;164(4):312-22. doi: 10.1016/j.trsl.2014.06.008. Epub 2014 Jun 25.
4
Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease.超重患者的血清脂肪因子水平及其与非酒精性脂肪性肝病的关系。
Panminerva Med. 2014 Jun;56(2):189-93.
5
Dietary recommendations for patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的饮食建议。
Prz Gastroenterol. 2014;9(1):18-23. doi: 10.5114/pg.2014.40845. Epub 2014 Mar 1.
6
Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.肥胖作为非酒精性脂肪性肝病和糖尿病的共同土壤:脂肪因子的作用
J Diabetes Investig. 2013 Sep 13;4(5):413-25. doi: 10.1111/jdi.12093. Epub 2013 May 6.
7
Psoriasis: to treat or to manage?银屑病:治疗还是管理?
Exp Dermatol. 2014 Oct;23(10):705-9. doi: 10.1111/exd.12437. Epub 2014 Aug 2.
8
Psoriasis and comorbidities: links and risks.银屑病及其合并症:关联与风险。
Clin Cosmet Investig Dermatol. 2014 Apr 17;7:119-32. doi: 10.2147/CCID.S44843. eCollection 2014.
9
The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients.肿瘤坏死因子-α抑制剂对银屑病患者维生素D状态的潜在影响。
Acta Derm Venereol. 2014 Nov;94(6):715-7. doi: 10.2340/00015555-1801.
10
More than skin-deep: the many dimensions of the psoriatic disease.不只是皮肤问题:银屑病疾病的多维度。
Swiss Med Wkly. 2014 Apr 24;144:w13968. doi: 10.4414/smw.2014.13968. eCollection 2014.

非酒精性脂肪性肝病与银屑病:咫尺天涯。

Non-alcoholic fatty liver disease and psoriasis: So far, so near.

作者信息

Ganzetti Giulia, Campanati Anna, Offidani Annamaria

机构信息

Giulia Ganzetti, Anna Campanati, Annamaria Offidani, Dermatologic Clinic, Polytechnic University of Marche Region, 60126 Ancona, Italy.

出版信息

World J Hepatol. 2015 Mar 27;7(3):315-26. doi: 10.4254/wjh.v7.i3.315.

DOI:10.4254/wjh.v7.i3.315
PMID:25848461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4381160/
Abstract

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and end-stage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases.

摘要

银屑病是一种慢性炎症性免疫介导的皮肤病,常伴有合并症。非酒精性脂肪性肝病(NAFLD)被定义为肝细胞内甘油三酯过度蓄积,包括从相对良性的脂肪变性到伴有脂肪浸润和小叶炎症的非酒精性脂肪性肝炎,再到肝硬化和终末期肝病等广泛的肝脏疾病状态。实际上,银屑病被认为是一种与合并症相关的全身性疾病,因为代谢综合征和NAFLD被视为代谢综合征的肝脏表现。银屑病、肥胖和代谢综合征之间的可能联系,这些都是已知的NAFLD风险因素,最近已有文献记载,重点关注脂肪组织在上述疾病共同的炎症背景发展中的关键作用。根据最近的数据,银屑病患者中NAFLD和代谢综合征的患病率高于普通人群。此外,与无银屑病的NAFLD患者相比,患有NAFLD和银屑病的患者发生严重肝纤维化的风险更高。这些病理状况之间的联系似乎是一种慢性低度炎症状态。本综述的目的是关注NAFLD和银屑病之间的多个方面的联系,这两种疾病表面上似乎并无关联。